-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 1, Hansen Pharmaceuticals announced that the lenalidomide capsules developed by its subsidiary, Jiangsu Hausen Pharmaceuticals, were approved.
According to data from Minai.
com, the sales of terminal lenalidomide capsules in China's public medical institutions in 2019 have exceeded 700 million yuan, and the first half of 2020 will increase by more than 90% year-on-year.
Among them, Xinji Pharmaceutical has the largest market share, Zhengda Tianqing Pharmaceutical Industry Group and Qilu Pharmaceutical rank second and third respectively.
Hansen Pharmaceuticals stated that the approval of the product will further enrich and improve the Group's oncology product line layout.
According to data from Minai.
com, the sales of terminal lenalidomide capsules in China's public medical institutions in 2019 have exceeded 700 million yuan, and the first half of 2020 will increase by more than 90% year-on-year.
Among them, Xinji Pharmaceutical has the largest market share, Zhengda Tianqing Pharmaceutical Industry Group and Qilu Pharmaceutical rank second and third respectively.
Hansen Pharmaceuticals stated that the approval of the product will further enrich and improve the Group's oncology product line layout.
Information, lenalidomide capsules anti -tumor drugs, the original research group for the new factory.
This product is suitable for the treatment of combined use of this product and dexamethasone to treat adult patients with multiple myeloma who have not been treated before and are not suitable for transplantation; this product is combined with dexamethasone to treat multiple patients who have received at least one therapy Adult patients with myeloma.
This product is suitable for the treatment of combined use of this product and dexamethasone to treat adult patients with multiple myeloma who have not been treated before and are not suitable for transplantation; this product is combined with dexamethasone to treat multiple patients who have received at least one therapy Adult patients with myeloma.
Sales of terminal lenalidomide capsules in Chinese public medical institutions in recent years
Source: Terminal competition landscape of China's public medical institutions
According to data from Menet.
com, the sales of terminal lenalidomide capsules in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly in recent years.
In 2019, it has exceeded 700 million yuan.
In the first half of 2020, a year-on-year growth of more than 90%, of which Xinji Pharmaceutical has the largest market share, Chia Tai Tianqing Pharmaceutical Group and Qilu Pharmaceutical rank second and third respectively.
It is worth noting that in recent years, with the efforts of domestic pharmaceutical companies, the market share of Xinji Pharmaceutical has declined rapidly, from the exclusive market in 2017 to 55% in the first half of 2020.
com, the sales of terminal lenalidomide capsules in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly in recent years.
In 2019, it has exceeded 700 million yuan.
In the first half of 2020, a year-on-year growth of more than 90%, of which Xinji Pharmaceutical has the largest market share, Chia Tai Tianqing Pharmaceutical Group and Qilu Pharmaceutical rank second and third respectively.
It is worth noting that in recent years, with the efforts of domestic pharmaceutical companies, the market share of Xinji Pharmaceutical has declined rapidly, from the exclusive market in 2017 to 55% in the first half of 2020.
Source: MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
At present, there are 6 manufacturers of lenalidomide capsules including Xinji Pharmaceutical, Zhengda Tianqing Pharmaceutical Group, Qilu Pharmaceutical, and Beijing Shuanglu Pharmaceutical.
Among them, Zhengda Tianqing Pharmaceutical Group and Beijing Shuanglu Pharmaceutical are based The supplementary application has been approved and reviewed, and Qilu Pharmaceutical, Yangzijiang Pharmaceutical Group, and Jiangsu Haosen Pharmaceutical have been approved for production in the 4 categories of imitations, which are deemed to have been reviewed.
In addition, the CSPC Pharmaceutical Europa, Changzhou Pharmaceutical Factory and other four companies submitted applications are listed in the review and approval (in the drug trial center).
Among them, Zhengda Tianqing Pharmaceutical Group and Beijing Shuanglu Pharmaceutical are based The supplementary application has been approved and reviewed, and Qilu Pharmaceutical, Yangzijiang Pharmaceutical Group, and Jiangsu Haosen Pharmaceutical have been approved for production in the 4 categories of imitations, which are deemed to have been reviewed.
In addition, the CSPC Pharmaceutical Europa, Changzhou Pharmaceutical Factory and other four companies submitted applications are listed in the review and approval (in the drug trial center).
Source: Announcements of listed companies, Minet.
com database
com database
On April 1, Hansen Pharmaceuticals announced that the lenalidomide capsules developed by its subsidiary, Jiangsu Hausen Pharmaceuticals, were approved.
According to data from Minai.
com, the sales of terminal lenalidomide capsules in China's public medical institutions in 2019 have exceeded 700 million yuan, and the first half of 2020 will increase by more than 90% year-on-year.
Among them, Xinji Pharmaceutical has the largest market share, Zhengda Tianqing Pharmaceutical Industry Group and Qilu Pharmaceutical rank second and third respectively.
Hansen Pharmaceuticals stated that the approval of the product will further enrich and improve the Group's oncology product line layout.
According to data from Minai.
com, the sales of terminal lenalidomide capsules in China's public medical institutions in 2019 have exceeded 700 million yuan, and the first half of 2020 will increase by more than 90% year-on-year.
Among them, Xinji Pharmaceutical has the largest market share, Zhengda Tianqing Pharmaceutical Industry Group and Qilu Pharmaceutical rank second and third respectively.
Hansen Pharmaceuticals stated that the approval of the product will further enrich and improve the Group's oncology product line layout.
Information, lenalidomide capsules anti -tumor drugs, the original research group for the new factory.
This product is suitable for the treatment of combined use of this product and dexamethasone to treat adult patients with multiple myeloma who have not been treated before and are not suitable for transplantation; this product is combined with dexamethasone to treat multiple patients who have received at least one therapy Adult patients with myeloma.
This product is suitable for the treatment of combined use of this product and dexamethasone to treat adult patients with multiple myeloma who have not been treated before and are not suitable for transplantation; this product is combined with dexamethasone to treat multiple patients who have received at least one therapy Adult patients with myeloma.
Sales of terminal lenalidomide capsules in Chinese public medical institutions in recent years
Source: Terminal competition landscape of China's public medical institutions
According to data from Menet.
com, the sales of terminal lenalidomide capsules in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly in recent years.
In 2019, it has exceeded 700 million yuan.
In the first half of 2020, a year-on-year growth of more than 90%, of which Xinji Pharmaceutical has the largest market share, Chia Tai Tianqing Pharmaceutical Group and Qilu Pharmaceutical rank second and third respectively.
It is worth noting that in recent years, with the efforts of domestic pharmaceutical companies, the market share of Xinji Pharmaceutical has declined rapidly, from the exclusive market in 2017 to 55% in the first half of 2020.
com, the sales of terminal lenalidomide capsules in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly in recent years.
In 2019, it has exceeded 700 million yuan.
In the first half of 2020, a year-on-year growth of more than 90%, of which Xinji Pharmaceutical has the largest market share, Chia Tai Tianqing Pharmaceutical Group and Qilu Pharmaceutical rank second and third respectively.
It is worth noting that in recent years, with the efforts of domestic pharmaceutical companies, the market share of Xinji Pharmaceutical has declined rapidly, from the exclusive market in 2017 to 55% in the first half of 2020.
Source: MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
At present, there are 6 manufacturers of lenalidomide capsules including Xinji Pharmaceutical, Zhengda Tianqing Pharmaceutical Group, Qilu Pharmaceutical, and Beijing Shuanglu Pharmaceutical.
Among them, Zhengda Tianqing Pharmaceutical Group and Beijing Shuanglu Pharmaceutical are based The supplementary application has been approved and reviewed, and Qilu Pharmaceutical, Yangzijiang Pharmaceutical Group, and Jiangsu Haosen Pharmaceutical have been approved for production in the 4 categories of imitations, which are deemed to have been reviewed.
In addition, the CSPC Pharmaceutical Europa, Changzhou Pharmaceutical Factory and other four companies submitted applications are listed in the review and approval (in the drug trial center).
Among them, Zhengda Tianqing Pharmaceutical Group and Beijing Shuanglu Pharmaceutical are based The supplementary application has been approved and reviewed, and Qilu Pharmaceutical, Yangzijiang Pharmaceutical Group, and Jiangsu Haosen Pharmaceutical have been approved for production in the 4 categories of imitations, which are deemed to have been reviewed.
In addition, the CSPC Pharmaceutical Europa, Changzhou Pharmaceutical Factory and other four companies submitted applications are listed in the review and approval (in the drug trial center).
Source: Announcements of listed companies, Minet.
com database
com database
On April 1, Hansen Pharmaceuticals announced that the lenalidomide capsules developed by its subsidiary, Jiangsu Hausen Pharmaceuticals, were approved.
According to data from Minai.
com, the sales of terminal lenalidomide capsules in China's public medical institutions in 2019 have exceeded 700 million yuan, and the first half of 2020 will increase by more than 90% year-on-year.
Among them, Xinji Pharmaceutical has the largest market share, Zhengda Tianqing Pharmaceutical Industry Group and Qilu Pharmaceutical rank second and third respectively.
Hansen Pharmaceuticals stated that the approval of the product will further enrich and improve the Group's oncology product line layout.
According to data from Minai.
com, the sales of terminal lenalidomide capsules in China's public medical institutions in 2019 have exceeded 700 million yuan, and the first half of 2020 will increase by more than 90% year-on-year.
Among them, Xinji Pharmaceutical has the largest market share, Zhengda Tianqing Pharmaceutical Industry Group and Qilu Pharmaceutical rank second and third respectively.
Hansen Pharmaceuticals stated that the approval of the product will further enrich and improve the Group's oncology product line layout.
Information, lenalidomide capsules anti -tumor drugs, the original research group for the new factory.
This product is suitable for the treatment of combined use of this product and dexamethasone to treat adult patients with multiple myeloma who have not been treated before and are not suitable for transplantation; this product is combined with dexamethasone to treat multiple patients who have received at least one therapy Adult patients with myeloma.
Tumor tumorThis product is suitable for the treatment of combined use of this product and dexamethasone to treat adult patients with multiple myeloma who have not been treated before and are not suitable for transplantation; this product is combined with dexamethasone to treat multiple patients who have received at least one therapy Adult patients with myeloma.
Sales of terminal lenalidomide capsules in Chinese public medical institutions in recent years
Source: Terminal competition landscape of China's public medical institutions
According to data from Menet.
com, the sales of terminal lenalidomide capsules in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly in recent years.
In 2019, it has exceeded 700 million yuan.
In the first half of 2020, a year-on-year growth of more than 90%, of which Xinji Pharmaceutical has the largest market share, Chia Tai Tianqing Pharmaceutical Group and Qilu Pharmaceutical rank second and third respectively.
It is worth noting that in recent years, with the efforts of domestic pharmaceutical companies, the market share of Xinji Pharmaceutical has declined rapidly, from the exclusive market in 2017 to 55% in the first half of 2020.
Hospital hospitalcom, the sales of terminal lenalidomide capsules in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly in recent years.
In 2019, it has exceeded 700 million yuan.
In the first half of 2020, a year-on-year growth of more than 90%, of which Xinji Pharmaceutical has the largest market share, Chia Tai Tianqing Pharmaceutical Group and Qilu Pharmaceutical rank second and third respectively.
It is worth noting that in recent years, with the efforts of domestic pharmaceutical companies, the market share of Xinji Pharmaceutical has declined rapidly, from the exclusive market in 2017 to 55% in the first half of 2020.
Source: MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
At present, there are 6 manufacturers of lenalidomide capsules including Xinji Pharmaceutical, Zhengda Tianqing Pharmaceutical Group, Qilu Pharmaceutical, and Beijing Shuanglu Pharmaceutical.
Among them, Zhengda Tianqing Pharmaceutical Group and Beijing Shuanglu Pharmaceutical are based The supplementary application has been approved and reviewed, and Qilu Pharmaceutical, Yangzijiang Pharmaceutical Group, and Jiangsu Haosen Pharmaceutical have been approved for production in the 4 categories of imitations, which are deemed to have been reviewed.
In addition, the CSPC Pharmaceutical Europa, Changzhou Pharmaceutical Factory and other four companies submitted applications are listed in the review and approval (in the drug trial center).
Business enterpriseAmong them, Zhengda Tianqing Pharmaceutical Group and Beijing Shuanglu Pharmaceutical are based The supplementary application has been approved and reviewed, and Qilu Pharmaceutical, Yangzijiang Pharmaceutical Group, and Jiangsu Haosen Pharmaceutical have been approved for production in the 4 categories of imitations, which are deemed to have been reviewed.
In addition, the CSPC Pharmaceutical Europa, Changzhou Pharmaceutical Factory and other four companies submitted applications are listed in the review and approval (in the drug trial center).
Source: Announcements of listed companies, Minet.
com database
com database
